FM
Frazier Management Portfolio holdings
AUM
$1.12M
Turnover
50%
1-Year Est. Return
151.58%
This Fund
S&P 500
This Quarter
Est. Return
+4.39%
1 Year Est. Return
+151.58%
3 Year Est. Return
+408.4%
5 Year Est. Return
+1,802.6%
10 Year Est. Return
–
AUM
$1.25B
AUM Growth
-$51.8M
(-4%)
Cap. Flow
+$301K
Cap. Flow
% of AUM
0.02%
Top 10 Holdings %
Top 10 Hldgs %
77.76%
Holding
39
New
4
Increased
7
Reduced
2
Closed
4
Avg Time Held
1.4
years
Top 10 Avg Time Held
1.5
years
Top 20 Avg Time Held
1.4
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Aclaris Therapeutics
ACRS
|
+$13.6M |
| 2 |
Immunovant
IMVT
|
+$13.4M |
| 3 |
ESSA Pharma
EPIX
|
+$7.36M |
| 4 |
Molecular Templates, Inc.
MTEM
|
+$6.22M |
| 5 |
AVDL
Avadel Pharmaceuticals
AVDL
|
+$4.67M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Collegium Pharmaceutical
COLL
|
+$18.9M |
| 2 |
Gritstone bio, Inc. Common Stock
GRTS
|
+$14.2M |
| 3 |
Rocket Pharmaceuticals
RCKT
|
+$9.21M |
| 4 |
Cardiff Oncology
CRDF
|
+$3.34M |
| 5 |
ARS Pharmaceuticals
SPRY
|
+$1.66M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 98.78% |
| 2 | Miscellaneous | 1.22% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
FRLN
26
DELISTED
Freeline Therapeutics Holdings plc American Depositary Shares
FRLN
| $6.76M | 0.54% |
36,667
| – | – |
2020 Q3
2 quarters
|
|
|
EPZM
27
DELISTED
Epizyme, Inc
EPZM
| $6.44M | 0.52% |
739,369
+7,933
| +1% | +$82.1K |
2020 Q4
1 quarter
|
|
|
AVDL
28
DELISTED
Avadel Pharmaceuticals
AVDL
| $5.23M | 0.42% |
+578,104
| New | +$4.67M |
2021 Q1
0 quarters
|
|
|
BLU
29
DELISTED
BELLUS Health Inc.
BLU
| $4.95M | 0.4% |
1,296,743
| – | – |
2020 Q3
2 quarters
|
|
|
ALNA
30
DELISTED
Allena Pharmaceuticals
ALNA
| $4.63M | 0.37% |
3,330,373
| – | – |
2017 Q4
13 quarters
|
|
|
SRRA
31
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
| $3.49M | 0.28% |
202,803
| – | – |
2015 Q4
21 quarters
|
|
|
32
Cardiff Oncology
CRDF
$75.6M
| $2.72M | 0.22% |
293,500
-275,000
| -48% | -$3.34M |
2020 Q3
2 quarters
|
|
33
DELISTED
Iterum Therapeutics
ITRM
| $2.17M | 0.17% |
102,554
| – | – |
2018 Q2
11 quarters
|
|
34
DELISTED
Galera Therapeutics, Inc. Common Stock
GRTX
| $2.13M | 0.17% |
241,000
| – | – |
2020 Q4
1 quarter
|
|
|
NBRV
35
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
| $707K | 0.06% |
17,026
| – | – |
2018 Q3
10 quarters
|
|
|
36
Collegium Pharmaceutical
COLL
$727M
| – | – |
-943,666
| Closed | -$18.9M | – |
|
37
Minerva Neurosciences
NERV
$112M
| – | – |
-7,693
| Closed | -$144K | – |
|
|
38
Rocket Pharmaceuticals
RCKT
$244M
| – | – |
-168,000
| Closed | -$9.21M | – |
|
|
39
ARS Pharmaceuticals
SPRY
$392M
| – | – |
-35,750
| Closed | -$1.66M | – |
|
Similar funds
ACMV
FRCMI
DB
NAM
AP
ID
CI
DIF
Frazier Management's Q1 2021 Portfolio in Review
As of Q1 2021, Frazier Management held 39 positions worth $1.25B, down 4% from $1.3B the previous quarter. Its ten largest holdings account for 78% of the portfolio.
Frazier Management's Q1 2021 filing shows 4 new, 7 increased, 2 reduced and 4 closed positions. Its largest new stake was Aclaris Therapeutics: 696,000 shares worth $17.5M. The largest sale was Collegium Pharmaceutical, an estimated $18.9M.
By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 99% a quarter earlier, followed by Miscellaneous.
- Frazier Management's largest Q1 2021 buy was Aclaris Therapeutics: 696,000 shares worth $17.5M.
- Frazier Management added most to Molecular Templates, Inc. in Q1 2021, an estimated $6.22M increase.
- Frazier Management's biggest Q1 2021 reduction was Gritstone bio, Inc. Common Stock, cutting an estimated $14.2M.
- Frazier Management fully exited Collegium Pharmaceutical in Q1 2021, selling an estimated $18.9M.
- Frazier Management's ten largest holdings make up 78% of its $1.25B portfolio in Q1 2021.
- Frazier Management opened 4 new positions and closed 4 in Q1 2021.
- Frazier Management's portfolio value fell 4% quarter-over-quarter to $1.25B.
Based on Frazier Management's 13F filing for Q1 2021, filed 12 May 2021.